

Revance Therapeutics, Inc.
Form 8-K
November 04, 2014

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2014

REVANCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State of incorporation)

001-36297
(Commission File No.)
Revance Therapeutics, Inc.

75-0551645
(IRS Employer Identification No.)

7555 Gateway Boulevard

Edgar Filing: Revance Therapeutics, Inc. - Form 8-K

Newark, California 94560

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: (510) 742-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 8.01 OTHER EVENTS.

On October 30, 2014, Revance Therapeutics, Inc. (the Company) submitted a comment letter to the U.S. Food and Drug Administration (the FDA) regarding the FDA's Draft Guidance for Industry, Upper Facial Lines: Developing Botulinum Toxin Drug Products (Docket No. 2014-D-0968), published in the Federal Register on August 6, 2014.

The text of the comment letter is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Number	Description
99.1	Comment Letter on FDA's Draft Guidance

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2014

Revance Therapeutics, Inc.

By: /s/ Lauren P. Silvernail
Lauren P. Silvernail
Executive Vice President, Corporate Development and
Chief Financial Officer

EXHIBIT INDEX

Number	Description
99.1	Comment Letter on FDA's Draft Guidance